Epigenomics said last week that its partner Abbott has launched an in vitro diagnostic test for colorectal cancer in Europe and the Asia/Pacific market.

The test is based on Epigenomics' Septin9 biomarker. Abbott holds non-exclusive worldwide rights to the biomarker under a licensing agreement signed in late 2007. It is optimized for Abbott's RealTime system m2000, an automated PCR platform.

Abbott is marketing the test as the Abbott RealTime mS9 Colorectal Cancer Assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.